Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. Issue 1 (February 2020)
- Record Type:
- Journal Article
- Title:
- Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. Issue 1 (February 2020)
- Main Title:
- Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles
- Authors:
- Goto, Eri
Horinaka, Shigeo
Ishimitsu, Toshihiko
Kato, Toru - Abstract:
- Abstract: Background: The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be inferred from their observed plasma concentrations; however, the steady-state pharmacokinetics (PK) of different FXa inhibitors have not been compared in clinically. Methods: The sensitivity of the rivaroxaban, apixaban, and edoxaban in the STA-Liquid Anti-FXa assay were compared, and the anti-FXa plasma concentrations were measured for PK assessments. Nonlinear mixed-effects modeling was used to assess population PK in 329 patients with nonvalvular atrial fibrillation or venous thromboembolism. Patients were followed up for an average of 3.6 years. Results: Sensitivity was similar among the three drugs in this assay, which could directly compare plasma concentrations instead of anti-FXa activities. Overall exposure was greatest in 5 mg BID apixaban relative to other drugs (p < 0.001). The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban. The PKs of 2.5 mg BID apixaban or 15 mg QD rivaroxaban were associated with hemorrhagic events. Conclusions: Apixaban was associated with greater exposure, higher trough concentrations in plasma compared with rivaroxaban or edoxaban. Furthermore, a higher plasma concentration may partially predict hemorrhagic events. Graphical abstract: Image 1
- Is Part Of:
- Drug metabolism and pharmacokinetics. Volume 35:Issue 1(2020)
- Journal:
- Drug metabolism and pharmacokinetics
- Issue:
- Volume 35:Issue 1(2020)
- Issue Display:
- Volume 35, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 35
- Issue:
- 1
- Issue Sort Value:
- 2020-0035-0001-0000
- Page Start:
- 151
- Page End:
- 159
- Publication Date:
- 2020-02
- Subjects:
- Apixaban -- Rivaroxaban -- Edoxaban -- Atrial fibrillation -- Venous thromboembolism -- anti-FXa activity -- Plasma concentration -- Population pharmacokinetics
Drugs -- Metabolism -- Periodicals
Pharmacokinetics -- Periodicals
615.7 - Journal URLs:
- http://www.sciencedirect.com/science/journal/13474367 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.dmpk.2019.10.005 ↗
- Languages:
- English
- ISSNs:
- 1347-4367
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.328000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12917.xml